Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 32.0 kDa. The protein migrates as 45-60 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>90% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human CD19 (20-291) Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).
Immobilized Human CD19 (20-291) Protein, His Tag (Cat. No. CD9-H53H4) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a with a linear range of 0.1-3 ng/mL (QC tested).
Anti-CD19 Antibody, Human IgG1 captured on Protein A Chip can bind Human CD19 (20-291) Protein, His Tag (Cat. No. CD9-H53H4) with an affinity constant of 3.49 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).
Emerging VoCs, Omicron, Delta, Beta, Alpha mutants and so on, including RBD, S trimer, S1, NTD, NP, etc. These mutants are of high purity and bioactivity and can be used to evaluate the efficacy of the antibodies and vaccination.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
CD3 proteins and a collection of for bispecific antibody development which are of high specificity and bioactivities and suitable for immunization, antibody screening.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
The MABSOL biotinylated protein collection includes more than a hundred commonly studied drug targets and biomarker proteins.
Comprehensive cytokines including IL families, growth factors, chemokines, TNFs, etc. These products are HEK293 expressed and nearly in authentic structure, high purity and bioactivity, cell based assay/SPR/BLI verified.
To support preclinical/clinical immunogenicity and PK analysis, ACROBiosystems has developed a series of high-affinity anti-idiotypic antibodies. Our pipeline covers five hot targets including adalimum*b, rituxim*b, cetuxim*b, trastuzum*b, and bevacizum*b.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tisagenlecleucel | CART-019; CTL-019; CART-19; LG-740 | Approved | Novartis Pharma Ag, University Of Pennsylvania | Kymriah | EU | Lymphoma, Follicular | Novartis Europharm Ltd | 2017-08-30 | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Plasmablastic Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic | Details |
Lisocabtagene maraleucel | Liso-Cel; JCAR-017 | Approved | Fred Hutchinson Cancer Research Center, Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute | Breyanzi | EU | Mediastinal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular | Bristol-Myers Squibb Pharma Eeig | 2021-02-05 | Lymphoma, B-Cell; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Immune System Diseases; Mediastinal Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Brexucabtagene autoleucel | KTE-X19; FKC-889 | Approved | Kite Pharma Inc, Gilead Sciences Inc | Tecartus | EU | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Kite Pharma Eu Bv | 2020-07-24 | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Relmacabtagene autoleucel | JWCAR-029 | Approved | Suzhou Yaomingjunuo Biotechnology Co Ltd | 倍诺达, Carteyva | Mainland China | Lymphoma, Large B-Cell, Diffuse | Jw Therapeutics (Shanghai) Co Ltd | 2021-09-01 | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Axicabtagene ciloleucel | FKC-876; KTE-C19; KTE C19 | Approved | Cabaret Biotech, Gilead Sciences Inc | Yescarta, 奕凯达 | Mainland China | Lymphoma, Large B-Cell, Diffuse; Primary mediastinal B cell lymphoma; Lymphoma, B-Cell | Fosun Kite Biotechnology Co Ltd | 2017-10-18 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
Blinatumomab | MEDI-538; MT-103; BiTE-MT-103; bscCD19xCD3; AMG-103 | Approved | Amgen Inc | Blincyto, 倍利妥 | Mainland China | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Amgen Inc | 2014-12-03 | Lymphoma, B-Cell; Leukemia; Neoplasm, Residual; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Philadelphia Chromosome; Lymphoma, Non-Hodgkin; Burkitt Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Loncastuximab tesirine | ADCT-402 | Approved | Adc Therapeutics Sa | Lonca, ZYNLONTA | United States | Lymphoma, Large B-Cell, Diffuse | Adc Therapeutics Sa | 2021-04-23 | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoproliferative Disorders; Burkitt Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Inebilizumab | 16C4-aFuc; MEDI-551; MT-0551; VIB-0551 | Approved | Duke University, Horizon Therapeutics Plc | Uplinza, Uplizna, ユプリズナ | Taiwan | Neuromyelitis Optica | Tai Tien Pharmaceuticals Co Ltd | 2020-06-11 | Lymphoma, B-Cell; Hematologic Neoplasms; Myasthenia Gravis; Rejection of renal transplantation; Immunoglobulin G4-Related Disease; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Scleroderma, Systemic; Multiple Sclerosis; Neuromyelitis Optica; Leukemia, Lymphocytic, Chronic, B-Cell; Encephalitis | Details |
Tafasitamab | XmAb-5574; MOR-208; XENP-5574; MOR-00208 | Approved | Xencor Inc | MONJUVI | EU | Lymphoma, Large B-Cell, Diffuse | Incyte Biosciences Distribution Bv | 2020-07-31 | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Fully human anti CD19 CAR-T Cell Therapy (University Hospitals Cleveland Medical Center) | Phase 1 Clinical | University Hospitals Cleveland Medical Center | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD20 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
aCD19z | aCD19z | Phase 1 Clinical | Christie Hospital Nhs Foundation Trust | Lymphoma, Non-Hodgkin | Details |
PTG-01 | PTG-01 | Phase 1 Clinical | Protheragen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
H-31970-SAGAN | H-31970-SAGAN | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Leidos Biomedical Research) | Clinical | Leidos | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Virus-specific-CD19.CAR | Phase 1 Clinical | Baylor College Of Medicine | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR T-cell therapy (Southwest Hospital Chongqing) | Phase 2 Clinical | Southwest Hospital Chongqing | Lymphoma, Large B-Cell, Diffuse | Details | |
CD19.CAR-VST | CD19.CAR-VST | Phase 1 Clinical | Baylor College Of Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T cell therapy (Wuhan Bio-Raid) | Phase 2 Clinical | Wuhan Bio-Raid Biotechnology | Hematologic Diseases; Lymphoma, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Japan Tissue Engineering) | Phase 1 Clinical | Nagoya University, Shinshu University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
1928-zT-2 (Guangzhou Institutes of Biomedicine and Health) | Phase 1 Clinical | Guangzhou Institute Of Biomedicine And Health, Chinese Academy Of Sciences | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Shenzhen Institute for Innovation and Translational Medicine) | yinnuokati-19 | Phase 2 Clinical | Dongguan People'S Hospital, Shenzhen Institute For Innovation & Translational Medicine | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Nanjing Medical University) | XLCART-001 | Phase 2 Clinical | Nanjing Medical University | Lymphoma, B-Cell | Details |
Anti-CD19 and anti-CD22 CAR T cell therapy (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells (City of Hope Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, Non-Hodgkin | Details | |
CD19/CD20 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Lymphoma, B-Cell | Details | |
Anti-CD19 CAR CIK-cell therapy (Formula Pharmaceuticals) | CARCIK-CD19; CIK-CAR.CD19 | Phase 2 Clinical | Fondazione Matilde Tettamanti Menotti De Marchi Onlus | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
U-CART (Shanghai Bioray Laboratory Inc) | Phase 2 Clinical | Hematologic Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | ||
Anti-CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | Phase 2 Clinical | The First Affiliated Hospital Of Nanchang University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Sinobioway) | Phase 2 Clinical | Sinobioway Biomedicine Co Ltd | Lymphoma, Large B-Cell, Diffuse; Lymphoma | Details | |
Anti-CD19 single-stranded antibody CAR T-cell therapy (Beijing Yongtai Rec Biotechnology) | Phase 1 Clinical | Beijing Yongtai Rec Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19 CAR-T cell therapy (National University of Malaysia) | Phase 3 Clinical | National University Of Malaysia | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CART-19 cells (Henan Hualong Biotechnology) | Phase 2 Clinical | Henan Hualong Biotechnology | Leukemia, Lymphoid | Details | |
Anti-CD19 CAR-T Cells (Yan'an Affiliated Hospital of Kunming Medical University) | Phase 1 Clinical | Kunming Medical University | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD7 and anti-CD19 chimeric antigen receptor T cell therapy | GC-197 | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19 CAR-T (HuaDao CAR-Tcell) | Phase 1 Clinical | Huadao (Shanghai) Biopharma Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
K-193 | K-193 | Phase 1 Clinical | Beijing Lvzhu Biological Technology Co Ltd | Lymphoma, B-Cell | Details |
CLBR-001/SWI-019 | CLBR-001/SWI-019 | Phase 1 Clinical | Abbvie Inc, California Institute For Biomedical Research | Lymphoma, B-Cell | Details |
NCAR19-T | Phase 2 Clinical | Second Military Medical University Of Chinese People'S Liberation Army | Lymphoma, B-Cell | Details | |
19273-4SCAR | 19273-4SCAR | Phase 2 Clinical | Peking University | Lymphoma, B-Cell | Details |
CD19 PD-1/CD28 CAR-T Cell Therapy (Second Affiliated Hospital School Of Zhejiang University School Of Medicine) | Phase 1 Clinical | Second Affiliated Hospital Of Zhejiang University School Of Medicine | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma | Details | |
MCM-998 | MCM-998; LXG-250 | Phase 1 Clinical | Novartis Pharma Ag | Multiple Myeloma | Details |
CC-312 | CC-312 | Phase 1 Clinical | Details | ||
Anti-CD19/22-CAR vector-transduced T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | People'S Liberation Army General Hospital Military Service | Leukemia; Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (iCarTAB BioMed) | Phase 1 Clinical | Leukemia; Lymphoma | Details | ||
dPD-1 hCD19 CART cell therapy (Innovative Cellular Therapeutics) | ICTCAR-014 | Phase 2 Clinical | Innovative Cellular Therapeutics Co Ltd | Lymphoma, Non-Hodgkin | Details |
Ensomafusp alfa | RG-6076 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Details | |
CTA-101 | CTA-101 | Phase 1 Clinical | Nanjing Bioheng Biotech Co Ltd, Nanjing Medical University, Xuzhou Medical University (Xzmu) | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
SGN-CD19B | SGN-CD19B | Seattle Genetics Inc | Details | ||
19(T2)28z1xx Chimeric Antigen Receptor (CAR) Modified T Cells | TAK-940 | Takeda | Neoplasms | Details | |
Autologous humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (First Affiliated Hospital of Zhejiang University) | Phase 1 Clinical | First Affiliated Hospital Of Zhejiang University | Lymphoma, Large B-Cell, Diffuse | Details | |
Anti-human CD19-CD22 T cell therapy | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CAR-T2 cell therapy (Nanfang Hospital of Southern Medical University) | Phase 2 Clinical | Nanfang Hospital Of Southern Medical University | Leukemia, Biphenotypic, Acute | Details | |
CD19/CD22 dual-target CAR-T cell therapy (Shenzhen University General Hospital) | Phase 2 Clinical | Shenzhen University General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anbalcabtagene autoleucel | CRC-01 | Curocell Inc | Details | ||
RGV-004 | RGV-004 | Phase 1 Clinical | Hangzhou Rongu Biotechnology Co Ltd | Lymphoma, B-Cell | Details |
Anti-CD19 and anti-CD22 CAR-T cell therapy(IASO Biotherapeutics) | CT-120 | Phase 2 Clinical | Nanjing Iaso Biotherapeutics Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
Obecabtagene autoleucel | AUTO1; Obe-cel; AUTO-1 | University College London | Details | ||
CD19x22 CAR T Cell Therapy (University Of Colorado Denver) | Phase 1 Clinical | University Of Colorado, Denver, Usa | Lymphoma, Non-Hodgkin | Details | |
GC-502 | GC-502 | Details | |||
ALLO-501A | ALLO-501A | Allogene Therapeutics Inc | Details | ||
Allogeneic CD-19 CAR-T Cell Therapy | Shenzhen University General Hospital | Details | |||
CD19-CART (Express 4-1BB, Unicar-Therapy Bio-medicine Technology) | Details | ||||
IMJ-995 | IMJ-995 | Novartis Pharma Ag | Details | ||
SNUH-CD19-CAR-T Cell Therapy | SNUH-CD19-CAR-T | Seoul National University Hospital | Details | ||
CD19-UCART | CD-19-UCART; CD19-UCART | Phase 1 Clinical | Bioray Laboraytories Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
BinD-19 (Shenzhen BinDeBio) | BinD-19 | Shenzhen Bindebio Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CART (Unicar-Therapy Bio-medicine Technology) | Details | ||||
YTB-323 | YTB-323 | Phase 2 Clinical | Novartis Pharma Ag | Lymphoma, Large B-Cell, Diffuse | Details |
CD19-CART (IL-6 secretion knockdown, Unicar-Therapy Bio-medicine Technology) | ssCART-19 | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
BCMA/CD19 CAR-T cell therapy (The First Affiliated Hospital of Nanchang University) | The First Affiliated Hospital Of Nanchang University | Details | |||
Autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy (University of Alberta) | University Of Alberta | Details | |||
Anti-CD19 CAR T-cell therapy (University College London) | 4G7-CARD | University College London | Details | ||
Anti-CD19 CAR T cell therapy (Shanghai GeneChem) | Shanghai Genechem Co Ltd | Details | |||
XYF19 CAR-T Cell Therapy | XYF-19 | Xi'An Yufan Biotechnology Co Ltd | Details | ||
Humanized anti-CD19 and anti-CD20 dual specific CAR-T cell therapy (Fujian Medical University) | Fujian Medical University | Details | |||
pCAR-19B | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
AFM-11 | AFM-11 | Affimed | Details | ||
Anti-CD19 CAR T-cell therapy (Sheba Medical Center) | Chaim Sheba Medical Center At Tel Hashomer | Details | |||
MDX 1342 | MDX-1342 | Medarex | Details | ||
CAR-T 19 cell therapy (University of Pennsylvania) | University Of Pennsylvania | Details | |||
A-319 | A-319 | Phase 1 Clinical | Evive Biotech Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
IKS-03 | IKS-03 | Phase 1 Clinical | Iksuda Therapeutics | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell | Details |
CD19 CAR engineered autologous T-cells Therapy(Sabz Biomedicals) | Phase 1 Clinical | Sabz Biomedicals | Leukemia, Biphenotypic, Acute | Details | |
CD19-targeted chimeric antigen receptor T-cell(Pell Bio-Med Technology) | PL-001 | Phase 2 Clinical | Pell Bio-Med Technology Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma | Details |
TNB-486 | TNB-486 | Phase 1 Clinical | Teneobio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Non-Hodgkin | Details |
bispecific CD19/CD22 CAR T-cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details | |
ICT19G1 | ICT-19G1 | Phase 1 Clinical | Innovative Cellular Therapeutics Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19 chimeric antigen receptor T cell therapy (Takara Bio) | TBI-1501 | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Takara Bio Inc | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Senl-1904A | Senl-1904A; Senl_1904A | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
MC-19PD1 CAR-T cell therapy (Peking University) | Phase 1 Clinical | Peking University | Lymphoma | Details | |
CD19 UCAR-T cell therapy (Shanghai Longyao Biotechnology) | Phase 1 Clinical | Shanghai Longyao Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) | Phase 1 Clinical | Tianjin Mycure Medical Technology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR T-cell therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Lymphoma, B-Cell | Details | |
GNR-084 | GNR-084 | Phase 2 Clinical | Generium Pharmaceuticals, Iontas | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19-STAR-T cell therapy (China Immunotech Co Ltd) | Phase 1 Clinical | Hebei Yanda Hospital, China Immunotech Co Ltd | Lymphoma, B-Cell | Details | |
CAR-NK019(Second Affiliated Hospital, School of Medicine, Zhejiang University) | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | ||
CD19/CD22 dual-target CAR-T (Yake biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
RO-7227166 | RO-7227166 | Phase 1 Clinical | F. Hoffmann-La Roche Ltd | Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR T-cell therapy (Nanjing CART Medical Technology) | Clinical | Nanjing Kati Medical Technology Co Ltd | Neoplasms | Details | |
BZ019 | BZ-019 | Phase 2 Clinical | Shanghai Cell Therapy Group Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Primary mediastinal B cell lymphoma; Lymphoma | Details |
Anti-CD22/CD19 monoclonal antibody-toxin conjugate | Phase 1 Clinical | The University Of Texas Southwestern Medical Center | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19-CD22 CAR-T cells (Shanghai Ultra-T Immune Therapeutics) | Phase 2 Clinical | Shanghai Ultra-T Immune Therapeutics Co LTD | Lymphoma, B-Cell; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
ET190L1-ARTEMIS T cells (Eureka Therapeutics) | ET190L1-ARTEMI; ET-190; ET190L1; ET190 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-CD19 CAR-T cell therapy (Juno Therapeutics) | Phase 1 Clinical | Leukemia, Lymphocytic, Chronic, B-Cell | Details | ||
Bispecific CD19/22 CAR T cells | Phase 2 Clinical | Lymphoma, Non-Hodgkin; Lymphoma | Details | ||
3rd-gen-CD19-CAR | 3rd-gen-CD19-CAR | Phase 2 Clinical | Bluebird Bio Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
FT-819 | FT-8198; FT-819 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
FT-596 | FT-596 | Phase 1 Clinical | Fate Therapeutics Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
4G7SDIE | Clinical | Synimmune Gmbh, The University Of Tubingen | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
U-01 | U-01 | Phase 1 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Leukemia; Leukemia, B-Cell | Details |
Anti-CD19 CAR-T cell therapy (Pinze Lifetechnologies) | PZ-01 | Clinical | Pinze Lifetechnology Co Ltd | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
Anti-CD19 anti-CD22 bispecific chimeric antigen receptor T cell therapy (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | Leukemia, Lymphoid | Details | |
Anti-CD19 chimeric antigen receptor T cell therapy (Immune cell) | Phase 1 Clinical | Immune Cell Inc | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
Anti-CD19+/BCMA CAR-T cells (Hrain Biotechnology) | Phase 1 Clinical | Hrain Biotechnology Co Ltd | POEMS Syndrome | Details | |
Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes (Fred Hutchinson Cancer Research Center) | Phase 1 Clinical | Fred Hutchinson Cancer Research Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary mediastinal B cell lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details | |
C-CAR039 | EXP-039; C-CAR039; C-CAR-039 | Phase 1 Clinical | Lymphoma, Non-Hodgkin | Details | |
CAR-20-19-22 | CAR-20-19-22 | Phase 1 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19/22 Bi-specific CAR-T Cell Therapy(Shenzhen Geno-Immune Medical Institute) | 4SCAR19/22 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19/79b Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | bi-4SCAR CD19/79b | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
MB-CART19.1 (Miltenyi Biotec) | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T therapy (Wuhan Sian Medical Technology) | Phase 3 Clinical | Wuhan Si'an Medical Technology Co Ltd, Xiangyang Central Hospital, Jingzhou Central Hospital, Wuhan Union Hospital, The First People'S Hospital Of Yuhang District | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Burkitt Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
HuCART19 | Phase 2 Clinical | National Cancer Institute | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Zamtocabtagene autoleucel | MB-CART2019.1 | Phase 2 Clinical | Miltenyi Biotec | Lymphoma, Large B-Cell, Diffuse | Details |
CD3/CD19 neg allogeneic BMT (National Institute of Allergy and Infectious Diseases/University of Pittsburgh) | Phase 2 Clinical | National Institute Of Allergy And Infectious Diseases (Niaid), University Of Pittsburgh | Primary Immunodeficiency Diseases; Female Urogenital Diseases; Inflammation | Details | |
Anti-CD19 universal CAR-T cell therapy (Chongqing Xinqiao Hospital) | Phase 1 Clinical | Xinqiao Hospital, Army Medical University | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
4-1BBz CD19-Her2tG (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Neoplasms; Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) | 4SCAR-19 | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Hrain Biotechnology) | Phase 2 Clinical | Shanghai Zhongshan Hospital, Hrain Biotechnology Co Ltd | Candidiasis, Vulvovaginal; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD20-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Lymphoma, B-Cell; Leukemia, B-Cell | Details | ||
CLIC-1901 (Ottawa Hospital Research Institute) | CLIC-1901 | Phase 2 Clinical | Ottawa Hospital Research Institute | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Chimeric antigen receptor T cell therapeutics (targeted CD19/CD20/CD22/CD30,Shanghai Unicar-Therapy Bio-medicine) | Phase 2 Clinical | Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd | Pancreatic Neoplasms; Lymphoma, Non-Hodgkin | Details | |
Anti-CD19 CAR-T cell therapy (Bellicum Pharmaceuticals) | BPX-401 | Phase 2 Clinical | Bellicum Pharmaceuticals Inc, Ospedale Pediatrico Bambino Gesu | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma | Details |
Anti-CD19 and anti-CD20 CAR-T cell therapy (Medical College of Wisconsin) | CAR-20/19-T cells | Phase 2 Clinical | The Medical College Of Wisconsin Nonprofit | Lymphoma, B-Cell; Lymphoma, B-Cell, Marginal Zone; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
Murine CD19 CAR-T cell therapy (Yake) | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
PBLTT52CAR19 | Phase 1 Clinical | Great Ormond Street Hospital For Children Nhs Foundation Trust | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/BCMA-targeted CAR-T Cell Therapy (Zhejiang University) | Phase 1 Clinical | Zhejiang University | Nephritis; Sjogren's Syndrome; Scleroderma, Systemic; Autoimmune Diseases; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CTA-30X | CTA30X; CTA-30X | Phase 1 Clinical | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
CAR-NK-CD19 Cell Therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan Union Hospital | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Anti-CD19 CAR-T cell therapy (Zhongyuan Union Cell & Gene Engineering) | Phase 1 Clinical | Institute Of Hematology & Blood Diseases Hospital | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/70 Bi-specific CAR-T Cell Therapy (Shenzhen Geno-Immune Medical Institute) | Phase 2 Clinical | Shenzhen Geno-Immune Medical Institute | Lymphoma, B-Cell | Details | |
CD19-CAR-T cell therapy (China Immunotech Co., Ltd.) | Phase 1 Clinical | China Immunotech Co Ltd, Hebei Yanda Ludaopei Hospital | Lymphoma, B-Cell | Details | |
Anti-CD19 CAR T-cell therapy (Dana-Farber Cancer Institute/Memorial Sloan-Kettering Cancer Center/Boston Children's Hospital) | Phase 2 Clinical | Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Boston Children'S Hospital | Leukemia | Details | |
Humanized CD19 CAR-T cell therapy (Yake) | YK-C19 | Phase 1 Clinical | Shanghai YaKe Biotechnology Co Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19 CARvac T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Lymphoma, B-Cell; Leukemia, B-Cell | Details | ||
Anti CD19 chimeric antigen receptor T cell therapy (YaKe Biotechnology) | Phase 2 Clinical | Shanghai YaKe Biotechnology Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
TG-1801 | NI-1701; TG-1801 | Phase 1 Clinical | Novimmune Sa | Lymphoma, B-Cell | Details |
Autologous anti-CD19 chimeric antigen receptor T-cell therapy (Malaghan Institute of Medical Research) | WZTL002-1 | Phase 1 Clinical | The Malaghan Institute Of Medical Research | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19/CD20 bispecific CAR-T cells (Henan Cancer Hospital) | Phase 1 Clinical | Henan Provincial Cancer Hospital | Lymphoma, B-Cell | Details | |
Allogeneic EBV-specific anti-CD19 CAR-T cell therapy (Memorial Sloan-Kettering Cancer Center) | Phase 1 Clinical | Memorial Sloan Kettering Cancer Center | Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CTL-119 | CTL-119 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Multiple Myeloma | Details |
Anti-CD19/CD22 bispecific CAR-T cell therapy (The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine) | Phase 1 Clinical | The Second Affiliated Hospital Of Henan University Of Traditional Chinese Medicine | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Autologous CAR19 T lymphocytes Therapy | Phase 1 Clinical | Institute of Hematology and Blood Transfusion, Czech Republic | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details | |
Autologous hematopoietic stem cell therapy (YaKe Biotechnology) | Phase 1 Clinical | Zhejiang University | Lymphoma | Details | |
Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) therapy (KK Women's and Children's Hospital) | Phase 2 Clinical | Kk Women'S And Children'S Hospital | Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
CD19/CD20 CAR-T Cell Therapy (PersonGen) | Phase 1 Clinical | Persongen Biotherapeutics | Details | ||
ALLO-501 | ALLO-501 | Cellectis Sa | Details | ||
CD19 CAR-T cell therapy (The First Affiliated Hospital of Soochow University) | Phase 2 Clinical | The First Affiliated Hospital Of Soochow University, Suzhou University | Leukemia; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Dual anti-CD19/CD22 CAR‐T cell therapy (B-cell malignancies, Stanford University) | Phase 1 Clinical | Stanford University, Orca Biosystems Inc | Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm, Residual; Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details | |
GC019F | Phase 1 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
CD19.CAR T Cells (Heidelberg University Hospital) | Phase 2 Clinical | Heidelberg University Hospital | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
GC-022 | GC-022; GC-022F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Hematologic Neoplasms; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19-CD123 cCAR T-cells Therapy(iCell Gene Therapeutics) | ICG140 | iCell Gene Therapeutics LLC | Details | ||
TAK-007 | TAK-007 | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Lymphoma, Non-Hodgkin | Details |
CD19-CAR-DNT cells Therapy(Zhejiang Ruijiamei Biotechnologies Co Ltd) | Phase 1 Clinical | Zhejiang Ruijiamei Biotechnologies Co Ltd | Lymphoma, B-Cell | Details | |
Anti-CD19/CD22 CAR-T cell therapy (Jiao Tong University) | Phase 1 Clinical | Shanghai Jiaotong University, Shanghai General Hospital | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19 CAR-T cell therapy (Uppsala University) | Phase 2 Clinical | Uppsala University | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CD19-targeting humanized selective CAR-T cell therapy (Xuanwu Hospital, Beijing) | Phase 2 Clinical | Xuanwu Hospital Of Capital Medical University | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
ThisCART-19 | ThisCART-19; ThisCART19A; ThisCART19C; ThisCART19B | Phase 1 Clinical | Fundamenta Therapeutics Ltd | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, AIDS-Related; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma | Details |
Evoncabtagene pazurgedleucel | CTX-110 | Phase 1 Clinical | Crispr Therapeutics Ag | Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Recombinant humanized anti-CD19/CD3 bispecific antibody(New Time Pharmaceutical) | LNF-1904 | Phase 1 Clinical | Shandong New Time Pharmaceutical Co Ltd | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
Anti-BCMA/CD19 CAR-T Therapy(University College London) | Phase 1 Clinical | University College London | Multiple Myeloma | Details | |
CD19/CD20 bispecific chimeric antigen receptor (CAR)-T cell therapy (Jonsson Comprehensive Cancer Center) | Phase 1 Clinical | Uclas Jonsson Comprehensive Cancer Center | Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Azercabtagene zapreleucel | PBCAR-0191 | Phase 2 Clinical | Baxalta Incorporated | Hematologic Neoplasms; Leukemia, Lymphoid; Neoplasms; Lymphoma, Non-Hodgkin | Details |
ET-019002 | ET-019002 | Phase 1 Clinical | Eureka Therapeutics Inc | Lymphoma, B-Cell; Neoplasms | Details |
IM19CAR-T | Phase 2 Clinical | Beijing Yimiao Medical Technology Co Ltd | Hematologic Neoplasms; Leukemia; Neoplasms; Lymphoma, Mantle-Cell; Leukemia, B-Cell; Lymphoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
CC-97540 | CC-97540 | Phase 1 Clinical | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Lymphoma | Details | |
RG-6333 | RO-7443904 | Phase 1 Clinical | F. Hoffmann-La Roche Ag | Lymphoma, Non-Hodgkin | Details |
1-A-46 | 1A46; 1-A-46; CMG1A46; CMG1A-46; BR110 | Phase 2 Clinical | Chengdu Chimagen Biosciences Co Ltd, Hisun Biopharmaceutical Co Ltd, BioRay Pharmaceutical Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
Anti-CD19 CAR-Engineered NK Cells therapy (Simnova) | CAR-NK-CD19 | Phase 1 Clinical | Shanghai Simnova Biotechnology Co Ltd | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
BCMA-CD19 cCAR T cell therapy (iCell Gene Therapeutics) | Phase 1 Clinical | Icell Gene Therapeutics (Int'L) Ltd | Multiple Myeloma; Lupus Erythematosus, Systemic | Details | |
GB5005 chimeric antigen receptor T cell therapy (Genbase) | GB-5005 | Phase 1 Clinical | Shanghai Genbase Biotechnology Co Ltd, Shanghai Genechem Co Ltd | Leukemia, B-Cell | Details |
Anti-CD19 CAR T-cell therapy (Hebei Senlang Biotechnology) | SENL-B19 | Phase 2 Clinical | Hebei Senlang Biological Technology Co Ltd | Lymphoma, B-Cell; Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma | Details |
JCAR-014 | JCAR-014 | Phase 2 Clinical | Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Juno Therapeutics Inc | Leukemia; Lymphoma, B-Cell; Leukemia, Lymphoid; Lymphoma, Large B-Cell, Diffuse; Hodgkin Disease; Candidiasis; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CAR-CD19 T cell therapy | Phase 2 Clinical | Lymphoma, Non-Hodgkin | Details | ||
Anti-CD19 chimeric antigen receptor T cell therapy (Innovative Cellular Therapeutics) | Phase 2 Clinical | Zhejiang University, Innovative Cellular Therapeutics Co Ltd, Kunming Medical University | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma | Details | |
Anti-CD19 and anti-CD22 CAR T cell therapy (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, B-Cell | Details | |
CD19/CD20 Dual CAR-T Cell Therapy (China Immunotech) | HX-s001; YTS101; HX-s001/YTS101; HXYT-001 | Phase 1 Clinical | Beijing Qingyi Taike Pharmaceutical Technology Co Ltd, China Immunotech Co Ltd | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
KUR-502 CD19 CAR-NKT | CMD-502; KUR-502 | Phase 1 Clinical | Athenex Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
CD19/CD20 bispecific CAR-T cells (Shanghai Cellular) | Phase 2 Clinical | Shanghai Cellular Biopharmaceutical Group Ltd | Lymphoma, B-Cell | Details | |
Anti-CD19-CAR γδT cells (Beijing Doing Biomedical) | Phase 1 Clinical | Leukemia; Lymphoma | Details | ||
Anti-CD19-CAR T cells (Beijing Doing Biomedical) | Phase 1 Clinical | Leukemia | Details | ||
Anti-CD19-CAR CMV-specific T-lymphocytes cell therapy (City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin | Details | |
UCART-19 | S-68587; UCART-19 | Phase 1 Clinical | Cellectis Sa | Leukemia, Lymphoid; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Details |
CD19- and CD22 specific CAR (Seattle Children's Hospital) | Phase 1 Clinical | Seattle Children'S Hospital | Leukemia; Lymphoma | Details | |
CN-201 | CN-201 | Phase 2 Clinical | Tongrun Biomedicine (Shanghai) Co Ltd | Lymphoma, B-Cell; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin | Details |
ISIKOK-19 | ISIKOK-19 | Phase 2 Clinical | Acibadem University | Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
KYV-101 | KYV-101 | Phase 1 Clinical | National Institutes Of Health, Kyverna Therapeutics Inc | Lupus Nephritis | Details |
Humanized CAR19T2 T Cell therapy(Zhaotai Cell Bio-tech) | Details | ||||
CD19-t-haNK | Phase 1 Clinical | Nantkwest Inc, Immunitybio Inc | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Lymphoma; Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin | Details | |
GC-012F | GC-012F | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Multiple Myeloma; Lymphoma, Non-Hodgkin | Details |
α/β CD3+/CD19+ cell depleted stem cell therapy (Mitchell Cairo) | Phase 2 Clinical | New York Medical College | Leukemia; Anemia; Thalassemia; Hodgkin Disease; Anemia, Aplastic; Lymphoma, Non-Hodgkin; Thrombocytopenia; Kostmann Syndrome; Anemia, Sickle Cell | Details | |
CD19/CD22 CAR-T cell therapy (Federal Research Institute of Pediatric Hematology, Oncology and Immunology) | Phase 2 Clinical | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | ||
KITE-363 | KITE-363 | Phase 1 Clinical | Kite Pharma | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse | Details |
Vadacabtagene leraleucel | 19-28z CAR T cells; 19-28z+ T cells; JCAR-015; JCAR-15; 19-28z-T-Cells | Phase 1 Clinical | Juno Therapeutics Inc, Memorial Sloan Kettering Cancer Center, Seattle Children'S Research Institute, Fred Hutchinson Cancer Research Center | Leukemia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
TC-110 | TC-110 | Phase 2 Clinical | Tcr2 Therapeutics Inc | Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Primary mediastinal B cell lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19-TriCAR-T/SILK Cell Therapy(Timmune Biotech) | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Leukemia | Details | |
iPD1 CD19 eCAR-T therapy (Marino Biotechnology) | Phase 1 Clinical | Chengdu Yinhe Biomedicine Co Ltd, Beijing Marino Biotechnology Co Ltd | Lymphoma, B-Cell; Glioblastoma | Details | |
TI-1007 | TI-1007 | Phase 1 Clinical | Tianjin Timmune Biotech Inc | Lymphoma, B-Cell | Details |
CD19 CAR-T cell therapy (Chongqing Precision Biotech) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
Autologous CD19/CD22 chimeric antigen receptor T-cell therapy (MD Anderson Cancer Center) | Phase 2 Clinical | The University Of Texas MD Anderson Cancer Center | Neoplasm, Residual; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CNTY-101 | CNTY-101 | Phase 1 Clinical | Century Therapeutics Llc | Lymphoma, B-Cell; Lymphoma, Non-Hodgkin | Details |
CD19 directed CAR T cell therapy (University of Colorado) | Phase 1 Clinical | University Of Colorado | Precursor Cell Lymphoblastic Leukemia-Lymphoma | Details | |
Anti-CD19-CAR T cell therapy (Kecellitics Biotech) | Phase 1 Clinical | Kecellitics Biotech Company Ltd | Leukemia | Details | |
C-CAR011 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Mantle-Cell; Lymphoma | Details | |
TanCART19/20 | Phase 1 Clinical | Pla General Hospital | Neuromyelitis Optica | Details | |
UCART019 | UCART-019 | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details |
CD19-PD1-CAR T cell therapy (Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell | Details | |
Dual specificity CD19 and CD20 or CD22 CAR-T cell therapy(Chinese PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, B-Cell; Leukemia, B-Cell | Details | |
CAR-T-19 Cell Therapy (The General Hospital Of The People'S Liberation Army) | Phase 1 Clinical | Pla General Hospital | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details | |
Emfizatamab | GNC-038 | Phase 2 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Extranodal NK-T-Cell; Lymphoma; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell | Details |
Allogenic Anti-CD19 gamma delta CAR-T cell therapy(PLA General Hospital) | Phase 2 Clinical | Pla General Hospital | Lymphoma, Non-Hodgkin | Details | |
CD19-CAR(The University Of Texas MD Anderson Cancer Center) | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Leukemia; Lymphoma | Details | |
Inaticabtagene Autoleucel | CNCT19; CNCT-19; HY001 | Phase 2 Clinical | Juventas Cell Therapy Ltd | Hematologic Neoplasms; Lymphoma, B-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin | Details |
CD19CAR(City Of Hope National Medical Center) | Phase 1 Clinical | City Of Hope National Medical Center, National Cancer Institute | Lymphoma, B-Cell; Leukemia, Hairy Cell; Lymphomatoid Granulomatosis; Central Nervous System Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
CD19-CART(Hrain) | Phase 2 Clinical | Hrain Biotechnology Co Ltd | Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Lymphoma, Follicular; Lymphoma, Mantle-Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details | |
AMG-562 | AMG-562 | Phase 1 Clinical | Amgen Inc | Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular | Details |
GC007g | GC-007G | Phase 2 Clinical | Gracell Biotechnologies (Shanghai) Co Ltd | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell | Details |
This web search service is supported by Google Inc.